Drug Discovery and Development

  • Home Drug Discovery and Development
  • Drug Discovery
  • Women in Pharma and Biotech
  • Oncology
  • Neurological Disease
  • Infectious Disease
  • Resources
    • Video features
    • Podcast
    • Voices
    • Webinars
  • Pharma 50
    • 2025 Pharma 50
    • 2024 Pharma 50
    • 2023 Pharma 50
    • 2022 Pharma 50
    • 2021 Pharma 50
  • Advertise
  • SUBSCRIBE

M&A Report: 2017 Was A Disruptive Year In Pharma, Biotech, And Other Markets

By Mike Botta | February 13, 2018

Mergermarket, an Acuris company, has released its global merger and acquisition trend report for the technology, media, and telecom (TMT) sector for 2017. Findings include M&A activity in the pharmaceutical, biotech, and healthcare industries.

Among key findings:

·         In 2017, global deal making in the TMT sector saw 3,389 deals worth a combined $498.2 billion. Although total deal value fell 26.3 percent compared to the $676.3 billion tallied in 2016, a new Mergermarket record (which dates back to 2001) by deal count was set, increasing by 233 transactions over 2016 (3,156 deals) to reach an all-time high

·         Such trends highlight the increasing influence of technology in just about everything, and how many industries have been finding themselves under pressure to, at times rapidly, incorporate digital tools in order to survive. This has forced consolidations in long-standing industries such as pharma, medical, and biotech

·         Amazon stayed busy throughout the year, disrupting markets. In what at the time was a somewhat surprising move, the company entered the consumer retail space with a bang, snatching up health food supermarket chain Whole Foods in June for $13.5 billion, its largest acquisition ever as well as the largest grocery deal in a decade.

In addition to disrupting the retail grocery market, the healthcare space also saw the emergence of Amazon in its midst. In a defensive move, CVS Health announced that it would be buying Aetna, an insurance carrier, for $67.8 billion in what amounted to the second-largest deal of the year, according to Mergermarket, which added that the move purportedly came after Amazon had led for licenses to operate pharmacy benefit management operations in multiple states, with more planned.

“That a Tech giant could cause such a shift in industry strategies as in the Pharma, Medical, & Biotech (PMB) sector demonstrates how eCommerce, Technology, and analytics have increasingly grown to be powerful tools capable of reshaping entire trades,” writes Elizabeth Lim, senior analyst and research editor – Americas, author of the report.

For the full Global Sector Overview, click here.

(Source: Mergermarket Limited)


Filed Under: Drug Discovery

 

Related Articles Read More >

EVEREST lead investigator on why Dupixent sets a new bar for treating coexisting CRSwNP and asthma
Sanders, King target DTC pharma ads but the industry worries more about threats to its $2B R&D model
Zoliflodacin wins FDA nod for treatment of gonorrhea
FDA approved ENFLONSIA for the prevention of RSV in Infants
“ddd
EXPAND YOUR KNOWLEDGE AND STAY CONNECTED
Get the latest news and trends happening now in the drug discovery and development industry.

MEDTECH 100 INDEX

Medtech 100 logo
Market Summary > Current Price
The MedTech 100 is a financial index calculated using the BIG100 companies covered in Medical Design and Outsourcing.
Drug Discovery and Development
  • MassDevice
  • DeviceTalks
  • Medtech100 Index
  • Medical Design Sourcing
  • Medical Design & Outsourcing
  • Medical Tubing + Extrusion
  • Subscribe to our E-Newsletter
  • Contact Us
  • About Us
  • R&D World
  • Drug Delivery Business News
  • Pharmaceutical Processing World

Copyright © 2025 WTWH Media LLC. All Rights Reserved. The material on this site may not be reproduced, distributed, transmitted, cached or otherwise used, except with the prior written permission of WTWH Media
Privacy Policy | Advertising | About Us

Search Drug Discovery & Development

  • Home Drug Discovery and Development
  • Drug Discovery
  • Women in Pharma and Biotech
  • Oncology
  • Neurological Disease
  • Infectious Disease
  • Resources
    • Video features
    • Podcast
    • Voices
    • Webinars
  • Pharma 50
    • 2025 Pharma 50
    • 2024 Pharma 50
    • 2023 Pharma 50
    • 2022 Pharma 50
    • 2021 Pharma 50
  • Advertise
  • SUBSCRIBE